# Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

> **NCT00252967** · PHASE3 · TERMINATED · sponsor: **Emory University** · enrollment: 64 (actual)

## Conditions studied

- Atrial Fibrillation
- Inflammation

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00252967
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** 2008-11
- **Final completion:** 2009-10
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** Insufficient power to show therapy difference at interim analysis.
- **Last updated:** 2014-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00252967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00252967, "Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00252967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*